Recent Interviews

Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".

Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".

John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)


Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"

19. January 2021 | 10:50 CET

Pfizer, Q&M Dental Group, Johnson & Johnson: Where do profiteers of the pandemic lurk?

  • Healthcare
Photo credits:

We all know that one's health is the most important thing. But from time to time, this truism slips out of focus. The pandemic has shown that neither fame nor money can protect you from getting sick. A big step toward being healthy, however, can be made by trusting in research. The development of vaccines in record time has shown how great the potential is in science and the pharmaceutical industry. New test methods are continually coming onto the market. Three shares show that there is money to be made on the stock market from these developments.

time to read: 3 minutes by Nico Popp
ISIN: SG2E73981531 , US4781601046 , US7170811035



Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author

Pfizer: The top dog with a clear strategy

Who wears the pants in the joint project between the German Company BioNTech and the US Company Pfizer becomes apparent when we look at the current delivery problems - while things are running smoothly in the US, the supply of vaccines in Europe continues to stall? But these problems should not change the expected good figures of the vaccine manufacturers - after all, no product in the world is currently more in demand than vaccine doses. Whoever invests in Pfizer receives, in addition to the justified Corona fantasy, a stake in ten other blockbusters, all of which account for more than a billion dollars in sales.

Pfizer's focus on biopharmaceuticals in recent years is a commitment to innovation. Generics and other drugs whose patent protection has expired are to be spun off. There is also a fantasy around Pfizer that the mRNA process, which partner BioNTech successfully used to develop its vaccine, may yield other innovative drugs in the future. The stock lost more than 16% over a one-year period. This development is disappointing, given the underlying conditions. However, given the dividend yield of slightly less than 4%, the stock may be an alternative for cautious investors.

Q&M Dental Group: Corona tests for Asia

A more speculative option is the stock of Singapore-based dental clinic operator Q&M Dental Group. The Company operates 114 practices in the island nation and also has a foot in the door in markets in Malaysia and China. During the first phase of the pandemic last year, demand for dental treatment plummeted in Singapore. But thanks to government support, the negative consequences for Q&M Dental Group were limited. Later, the Company acquired a stake in Acumen Diagnostics Pte, a manufacturer of corona tests. In September, Acumen finally received a license from the Ministry of Health to offer its clinical laboratory tests in Singapore.

Although Q&M Dental intends to maintain the core dental business it has successfully run since 1996, the need for rapid tests is creating fantasy around Q&M Dental's investment story. The dental practice chain is currently valued at around EUR 280 million and believes it will perform between 1,000 and 2,000 tests a day in Singapore in 2021.

Additionally, it plans to push its testing business with foreign countries to generate more revenue. Given the pandemic and the somewhat more challenging environment for dental treatments, Q&M Dental appears to be well-positioned with its new business around Corona tests. The share is traded in Germany but has not yet gained momentum.

Johnson & Johnson: Jack of all trades in the healthcare sector

One stock that may not be a high-flyer but has offered steady growth for years is Johnson & Johnson. The Company provides care and hygiene products, medical technology and also drugs. From successful products for psoriasis to cancer drugs, Johnson & Johnson has it all. In medical technology, the Company suffered a minor setback in 2020: Because many operations were postponed, sales in the division fell by double digits. But this effect is said to be only temporary. Although the figures for the first nine months of the fiscal year still show a small drop in sales of 2%, this effect could already be smaller in the full year's view.

While Johnson & Johnson is not known as a vaccine pioneer, the Company is working on a vaccine against the coronavirus. Although there have been setbacks in the clinical trials, the causes had nothing to do with the active ingredient. The Company operates very profitably and is also active in many areas of healthcare. On a one-year horizon, the stock delivered a zero return, but the price recently picked up speed, with it increasing more than 7% last month. The share is a reliable standard stock with good prospects. There are various ways to profit from the expected increased investment in the healthcare sector. Even standard stocks could have catch-up potential. Smaller niche stocks, such as Q&M Dental Group, score with their low profile and business in Asia's growth market.


Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author

Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.

Related comments:

17. March 2021 | 07:25 CET | by Nico Popp

Fresenius SE, Q+M Dental Group, Siemens Healthineers: Where growth meets dividends

  • Healthcare

The back-and-forth surrounding AstraZeneca's vaccine has unsettled many people. But the discussion about extremely rare side effects also shows: Vaccines and drugs are subject to strict regulations and the healthcare system is strictly regulated. While pharmaceutical companies must always expect setbacks, especially in accelerated approval procedures, the situation is different for suppliers of medical technology or consumables. We present three stocks that are benefiting from rising healthcare spending.


12. January 2021 | 10:28 CET | by Carsten Mainitz

CureVac, Q&M Dental, Moderna - What you didn't know - really exciting!

  • Healthcare

The World Health Organization (WHO) recorded more than 235 Covid-19 vaccine projects worldwide since January 2020, but few projects make it across the finish line. Timing is a critical factor, and early entrants will divide the huge market among themselves. These include BioNTech/Pfizer, Moderna and AstraZeneca. Still in the "test phase" is Tübingen-based CureVac, which recently entered into a sales cooperation with Bayer. Information published yesterday is positive and suggests approval of the preparation by the beginning of the second quarter of 2021 at the latest. Away from vaccine manufacturers, other Corona profiteers exist with which investors can earn handsomely. Q&M Dental from Singapore is little known. Its subsidiary is one of nine government-approved Corona testing facilities. Also, Q&M supplies Asian neighboring countries with millions of its Corona testing. We inform you about the news and potentials of known and unknown players.


18. June 2020 | 08:40 CET | by Mario Hose

BioNTech, Evotec, EXMceuticals - which stocks have the potential to double?

  • Healthcare

Experienced investors assume that the DAX, Germany's leading index, will still reach new highs in 2020. One of the best-known supporters of this scenario is the asset manager Dr. Jens Ehrhardt. Rising markets are supported by the measures taken by central banks and politicians - it is de facto the consequence of the increase in the money supply. This expected development will be of particular interest to those investors who have so far been on the sidelines and have to position themselves or reallocate.